Company intelligence / Profile preview

NeuroSense Therapeutics

Herzliya, Israel

Ownership: Public · NRSN
Employees: ~17
Development stage: Phase 3

Overview

Phase 2b PARADIGM trial showed PrimeC reduced ALS disease progression by 33-36% and improved survival rates by 43-58%. Complication-free survival showed 57-73% difference favoring PrimeC over placebo after 12 months.

Therapeutic areas: Neurology
Modalities: Small moleculesFixed-dose combination drugs
Industry: Biotech

Drug pipeline

3 assets

PrimeC

2 more assets in the full pipeline.

Request access →

Partnerships

In discussions with a global pharmaceutical company as of April 2025

Financials

Market cap: $11.7M
Total revenue: $0
Enterprise value: $11.7M

Beyond the preview

Go deeper on NeuroSense Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSense Therapeutics.

Explore the full profile